Hill, C. Microbiome and infection: A case for “selective depletion”. Ann. Nutr. Metab. 77(3), 4–9 (2021).Article
CAS
Google Scholar
Luo, Y. & Zhou, T. Connecting the dots: Targeting the microbiome in drug toxicity. Med. Res. Rev. 42(1), 83–111 (2022).Article
CAS
PubMed
Google Scholar
Woodhouse, C., Patel, V., Singanayagam, A. & Shawcross, D. the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 47(2), 192–202 (2018).Article
CAS
PubMed
Google Scholar
Sarin, S. K., Pande, A. & Schnabl, B. Microbiome as a therapeutic target in alcohol-related liver disease. J. Hepatol. 70(2), 260–272 (2019).Article
PubMed
Google Scholar
Martin, C. R., Osadchiy, V., Kalani, A. & Mayer, E. A. The brain-gut-microbiome axis. Cell. Mol. Gastroenterol. Hepatol. 6(2), 133–148 (2018).Article
PubMed
PubMed Central
Google Scholar
Dinan, T. G. & Cryan, J. F. The microbiome-gut-brain axis in health and disease. Gastroenterol. Clin. 46(1), 77–89 (2017).Article
Google Scholar
Ghaisas, S., Maher, J. & Kanthasamy, A. Gut microbiome in health and disease: Linking the microbiome–gut–brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol. Ther. 158, 52–62 (2016).Article
CAS
PubMed
Google Scholar
Chen, Y.-Y. et al. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. J. Transl. Med. 17(1), 1–11 (2019).Article
Google Scholar
Shankaranarayanan, D. & Raj, D. Gut microbiome and kidney disease. Clin. J. Am. Soc. Nephrol. (2022).Ahmadmehrabi, S. & Tang, W. W. Gut microbiome and its role in cardiovascular diseases. Curr. Opin. Cardiol. 32(6), 761 (2017).Article
PubMed
PubMed Central
Google Scholar
Okuyama, Y. et al. The influence of gut microbiome on progression of overactive bladder symptoms: A community-based 3-year longitudinal study in Aomori, Japan. Int. Urol. Nephrol. 54(1), 9–16 (2022).Article
CAS
PubMed
Google Scholar
Okamoto, T. et al. Altered gut microbiome associated with overactive bladder and daily urinary urgency. World J. Urol. 39(3), 847–853 (2021).Article
CAS
PubMed
Google Scholar
Patangia, D. V., Anthony Ryan, C., Dempsey, E., Paul Ross, R. & Stanton, C. Impact of antibiotics on the human microbiome and consequences for host health. MicrobiologyOpen. 11(1), e1260 (2022).Article
CAS
PubMed
PubMed Central
Google Scholar
Panda, S. et al. Short-term effect of antibiotics on human gut microbiota. PloS One 9(4), e95476 (2014).Article
ADS
PubMed
PubMed Central
Google Scholar
Villarreal, A. A., Aberger, F. J., Benrud, R. & Gundrum, J. D. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 111(1), 17–20 (2012).PubMed
Google Scholar
Shimodaira, Y., Watanabe, K. & Iijima, K. The risk of antibiotics and enterocolitis for the development of inflammatory bowel disease: A Japanese administrative database analysis. Sci. Rep. 12(1), 1–8 (2022).Article
Google Scholar
Ungaro, R. et al. Antibiotics associated with increased risk of new-onset Crohn’s disease but not ulcerative colitis: A meta-analysis. ACG 109(11), 1728–1738 (2014).CAS
Google Scholar
Vallianou, N., Dalamaga, M., Stratigou, T., Karampela, I. & Tsigalou, C. Do antibiotics cause obesity through long-term alterations in the gut microbiome? A review of current evidence. Curr. Obesity Rep. 10(3), 244–262 (2021).Article
Google Scholar
Ferrajolo, C. et al. Antibiotic-induced liver injury in paediatric outpatients: A case-control study in primary care databases. Drug Saf. 40(4), 305–315 (2017).Article
CAS
PubMed
Google Scholar
Stine, J. G. & Lewis, J. H. Hepatotoxicity of antibiotics: A review and update for the clinician. Clin. Liver Dis. 17(4), 609–642 (2013).Article
PubMed
Google Scholar
Ianiro, G., Tilg, H. & Gasbarrini, A. Antibiotics as deep modulators of gut microbiota: Between good and evil. Gut. 65(11), 1906–1915 (2016).Article
CAS
PubMed
Google Scholar
Melander, R. J., Zurawski, D. V. & Melander, C. Narrow-spectrum antibacterial agents. Medchemcomm. 9(1), 12–21 (2018).Article
CAS
PubMed
Google Scholar
Ostorhazi, E. et al. Advantage of a narrow spectrum host defense (antimicrobial) peptide over a broad spectrum analog in preclinical drug development. Front. Chem. 6, 359 (2018).Article
ADS
PubMed
PubMed Central
Google Scholar
Alm, R. A. & Lahiri, S. D. Narrow-spectrum antibacterial agents—Benefits and challenges. Antibiotics 9(7), 418 (2020).Article
CAS
PubMed
PubMed Central
Google Scholar
Mondhe, M., Chessher, A., Goh, S., Good, L. & Stach, J. E. Species-selective killing of bacteria by antimicrobial peptide-PNAs. PloS One 9(2), e89082 (2014).Article
ADS
PubMed
PubMed Central
Google Scholar
Chandra, N. Computational approaches for drug target identification in pathogenic diseases. Exp. Opin. Drug Discov. 6(10), 975–979 (2011).Article
CAS
Google Scholar
Garcia-Albornoz, M. A. & Nielsen, J. Application of genome-scale metabolic models in metabolic engineering. Ind. Biotechnol. 9(4), 203–214 (2013).Article
CAS
Google Scholar
Kim, W. J., Kim, H. U. & Lee, S. Y. Current state and applications of microbial genome-scale metabolic models. Curr. Opin. Syst. Biol. 2, 10–18 (2017).Article
Google Scholar
Gu, C., Kim, G. B., Kim, W. J., Kim, H. U. & Lee, S. Y. Current status and applications of genome-scale metabolic models. Genome Biol. 20(1), 1–18 (2019).Article
Google Scholar
Purdy, H. M. & Reed, J. L. Evaluating the capabilities of microbial chemical production using genome-scale metabolic models. Curr. Opin. Syst. Biol. 2, 91–97 (2017).Article
Google Scholar
Choi, K. R. et al. Systems metabolic engineering strategies: Integrating systems and synthetic biology with metabolic engineering. Trends Biotechnol. 37(8), 817–837 (2019).Article
CAS
PubMed
Google Scholar
Kim, T. Y., Kim, H. U. & Lee, S. Y. Metabolite-centric approaches for the discovery of antibacterials using genome-scale metabolic networks. Metab. Eng. 12(2), 105–111 (2010).Article
CAS
PubMed
Google Scholar
Jerby, L. & Ruppin, E. Predicting drug targets and biomarkers of cancer via genome-scale metabolic modeling. Clin. Cancer Res. 18(20), 5572–5584 (2012).Article
CAS
PubMed
Google Scholar
Cesur MF, Siraj B, Uddin R, Durmuş S, Çakır T. Network-based metabolism-centered screening of potential drug targets in Klebsiella pneumoniae at genome scale. Front. Cell. Infect. Microbiol. 447 (2020).Mohite, O. S., Weber, T., Kim, H. U. & Lee, S. Y. Genome-scale metabolic reconstruction of actinomycetes for antibiotics production. Biotechnol. J. 14(1), 1800377 (2019).Article
Google Scholar
Price, N. D., Reed, J. L. & Palsson, B. Ø. Genome-scale models of microbial cells: Evaluating the consequences of constraints. Nat. Rev. Microbiol. 2(11), 886–897 (2004).Article
CAS
PubMed
Google Scholar
Lewis, N. E., Nagarajan, H. & Palsson, B. O. Constraining the metabolic genotype–phenotype relationship using a phylogeny of in silico methods. Nat. Rev. Microbiol. 10(4), 291–305 (2012).Article
CAS
PubMed
PubMed Central
Google Scholar
O’Brien, E. J., Monk, J. M. & Palsson, B. O. Using genome-scale models to predict biological capabilities. Cell. 161(5), 971–987 (2015).Article
PubMed
PubMed Central
Google Scholar
Orth, J. D., Thiele, I. & Palsson, B. Ø. What is flux balance analysis?. Nat. Biotechnol. 28(3), 245–248 (2010).Article
CAS
PubMed
PubMed Central
Google Scholar
Kim, H. U., Kim, T. Y. & Lee, S. Y. Genome-scale metabolic network analysis and drug targeting of multi-drug resistant pathogen Acinetobacter baumannii AYE. Mol. BioSyst. 6(2), 339–348 (2010).Article
CAS
PubMed
Google Scholar
Perumal, D., Samal, A., Sakharkar, K. R. & Sakharkar, M. K. Targeting multiple targets in Pseudomonas aeruginosa PAO1 using flux balance analysis of a reconstructed genome-scale metabolic network. J. Drug Target. 19(1), 1–13 (2011).Article
CAS
PubMed
Google Scholar
Yeh, I., Hanekamp, T., Tsoka, S., Karp, P. D. & Altman, R. B. Computational analysis of Plasmodium falciparum metabolism: Organizing genomic information to facilitate drug discovery. Genome Res. 14(5), 917–924 (2004).Article
CAS
PubMed
PubMed Central
Google Scholar
Korcsmáros, T., Szalay, M. S., Böde, C., Kovács, I. A. & Csermely, P. How to design multi-target drugs: Target search options in cellular networks. Exp. Opin. Drug Discov. 2(6), 799–808 (2007).Article
Google Scholar
Zimmermann, G. R., Lehar, J. & Keith, C. T. Multi-target therapeutics: When the whole is greater than the sum of the parts. Drug Discov. Today 12(1–2), 34–42 (2007).Article
CAS
PubMed
Google Scholar
Talevi, A. Multi-target pharmacology: Possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective. Front. Pharmacol. 205 (2015).Schellenberger, J., Park, J. O., Conrad, T. M. & Palsson, B. Ø. BiGG: a Biochemical Genetic and Genomic knowledgebase of large scale metabolic reconstructions. BMC Bioinf. 11, 1–10 (2010).Article
Google Scholar
EPA U. Escherichia coli K‐12 final risk assessment: Attachment I—Final risk assessment of Escherichia coli K‐12 derivatives (1997).Letunic, I. & Bork, P. Interactive Tree Of Life (iTOL) v4: Recent updates and new developments. Nucl. Acids Res. 47(W1), W256–W259 (2019).Article
CAS
PubMed
PubMed Central
Google Scholar
Liao, Y.-C. et al. An experimentally validated genome-scale metabolic reconstruction of Klebsiella pneumoniae MGH 78578, i YL1228. J. Bacteriol. 193(7), 1710–1717 (2011).Article
CAS
PubMed
PubMed Central
Google Scholar
Lewis, L. A., Perisin, M. A., & Tobias, A. V. Metabolic modeling of Pseudomonas putida to understand and improve the breakdown of plastic waste. CCDC Army Research Laboratory Adelphi United States (2020).Monk, J. M. et al. iML1515, a knowledgebase that computes Escherichia coli traits. Nat. Biotechnol. 35(10), 904–908 (2017).Article
CAS
PubMed
PubMed Central
Google Scholar
Thiele, I. et al. A community effort towards a knowledge-base and mathematical model of the human pathogen Salmonella Typhimurium LT2. BMC Syst. Biol. 5(1), 1–9 (2011).Article
Google Scholar
Monk, J. M. et al. Genome-scale metabolic reconstructions of multiple Escherichia coli strains highlight strain-specific adaptations to nutritional environments. Proc. Natl. Acad. Sci. 110(50), 20338–20343 (2013).Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Charusanti, P. et al. An experimentally-supported genome-scale metabolic network reconstruction for Yersinia pestis CO92. BMC Syst. Biol. 5(1), 1–13 (2011).Article
Google Scholar
Sigurdsson, G., Fleming, R. M., Heinken, A. & Thiele, I. A systems biology approach to drug targets in Pseudomonas aeruginosa biofilm. PLoS One. 7(4), e34337 (2012).Article
ADS
CAS
PubMed
PubMed Central
Google Scholar
Cottarel, G. & Wierzbowski, J. Combination drugs, an emerging option for antibacterial therapy. Trends Biotechnol. 25(12), 547–555 (2007).Article
CAS
PubMed
Google Scholar
Kaelin, W. G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer. 5(9), 689–698 (2005).Article
CAS
PubMed
Google Scholar
Klobucar, K. & Brown, E. D. Use of genetic and chemical synthetic lethality as probes of complexity in bacterial cell systems. FEMS Microbiol. Rev. 42(1), fux054 (2018).Article
Google Scholar
Tyers, M. & Wright, G. D. Drug combinations: A strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17(3), 141–155 (2019).Article
CAS
PubMed
Google Scholar
Zhang, Y. Using synthetic-lethal interactions to discover antibacterial drug targets (2022).Dehghan Manshadi, M., Setoodeh, P. & Zare, H. Rapid-SL identifies synthetic lethal sets with an arbitrary cardinality. Sci. Rep. 12(1), 1–9 (2022).Article
Google Scholar
Kohanski, M. A., Dwyer, D. J. & Collins, J. J. How antibiotics kill bacteria: From targets to networks. Nat. Rev. Microbiol. 8(6), 423–435 (2010).Article
CAS
PubMed
PubMed Central
Google Scholar
Murima, P., McKinney, J. D. & Pethe, K. Targeting bacterial central metabolism for drug development. Chem. Biol. 21(11), 1423–1432 (2014).Article
CAS
PubMed
Google Scholar
Cormen, T. H., Leiserson, C. E., Rivest, R. L. & Stein, C. Greedy algorithms. Introduction Algorithms 1, 329–355 (2001).
Google Scholar
Wishart, D. S. et al. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46(D1), D1074–D1082 (2018).Article
CAS
PubMed
Google Scholar
Falagas, M. E., Athanasaki, F., Voulgaris, G. L., Triarides, N. A. & Vardakas, K. Z. Resistance to fosfomycin: Mechanisms, frequency and clinical consequences. Int. J. Antimicrob. Agents. 53(1), 22–28 (2019).Article
CAS
PubMed
Google Scholar
Zhang, Y., Wang, L., Zhou, C., Lin, Y., Liu, S., & Zeng, W., et al. Unraveling mechanisms and epidemic characteristics of nitrofurantoin resistance in uropathogenic Enterococcus faecium clinical isolates. Infect. Drug Resist. 1601–11 (2021).Christaki, E., Marcou, M. & Tofarides, A. Antimicrobial resistance in bacteria: Mechanisms, evolution, and persistence. J. Mol. Evol. 88, 26–40 (2020).Article
ADS
CAS
PubMed
Google Scholar